About the job
ABOUT US
At Invivyd, Inc., we are dedicated to safeguarding the health of over 9 million immunocompromised individuals in the United States. Our mission is to provide protection against serious viral infections, starting with SARS-CoV-2, through our innovative antibody development platform.
In March 2024, Invivyd received emergency use authorization (EUA) from the U. S. FDA for a monoclonal antibody in our pipeline. By October 2025, our Investigational New Drug (IND) application was approved, allowing us to advance the REVOLUTION clinical program for VYD2311, a groundbreaking monoclonal antibody aimed at preventing COVID-19.
Join us in making a significant impact in the healthcare landscape. Be part of Invivyd.
